Financial support: At the initiation of the study, POZEN was the IND sponsor of sumatriptan/naproxen sodium, which was transferred to GlaxoSmithKline after marketing approval in the USA (April 2008). GlaxoSmithKline financed, developed, and managed this study under both sponsors.
Long-Term Evaluation of Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents
Version of Record online: 28 JUL 2011
© 2011 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 51, Issue 9, pages 1374–1387, October 2011
How to Cite
McDonald, S. A., Hershey, A. D., Pearlman, E., Lewis, D., Winner, P. K., Rothner, D., Linder, S. L., Runken, M. C., Richard, N. E. and Derosier, F. J. (2011), Long-Term Evaluation of Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents. Headache: The Journal of Head and Face Pain, 51: 1374–1387. doi: 10.1111/j.1526-4610.2011.01965.x
Clinical Trial Registration Numbers: NCT00488514.
Conflict of Interest: S.A. McDonald, F.J. Derosier, M.C. Runken, and N. Richard receive salary and stock as employees of GlaxoSmithKline, the maker of sumatriptan and naproxen sodium (sumatriptan/naproxen sodium). A.D. Hershey participated on advisory boards for GlaxoSmithKline, Allergan, and MAP Pharmaceuticals, and received grant support and contracts from NIH/NINDS, Endo Pharmaceutical, and GlaxoSmithKline. E. Pearlman served as a consultant for GlaxoSmithKline, Merck, and Allergan, participated in Speaker's Bureau for Merck, Allergan, and GlaxoSmithKline, and received support for clinical trials from GlaxoSmithKline, Merck, Astra Zeneca, UCB, and Neuralieve. D. Lewis received a research grant from BMS, served as a consultant for study design only (Merck) and served as a consultant for study design and received a research grant from Astra Zeneca and GlaxoSmithKline. P.K. Winner served as a consultant (Allergan, GlaxoSmithKline, Merck, MAP Pharmaceuticals, Zogenix), participated in Speaker's Bureau (Allergan, GlaxoSmithKline, Merck, Zogenix), and received support for clinical trials (Allergan, GlaxoSmithKline, Merck, MAP Pharmaceuticals, Novartis, Pfizer). D. Rothner served as a consultant to GlaxoSmithKline, AstraZeneca, and MAP Pharmaceuticals and received research funding from GlaxoSmithKline and AstraZeneca. S.L. Linder participated on advisory boards and/or received funding from GlaxoSmithKline, Merck, Lilly, and AstraZeneca.
- Issue online: 5 OCT 2011
- Version of Record online: 28 JUL 2011
- Accepted for publication June 9, 2011.
Options for accessing this content:
- If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
- If your institution does not currently subscribe to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.